Cholesteryl Ester Storage Disease News and Research

RSS
Kanuma approved as first treatment for patients with LAL deficiency

Kanuma approved as first treatment for patients with LAL deficiency

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva BioPharma presents data on cholesteryl ester storage disease at NLA annual meeting

Synageva BioPharma presents data on cholesteryl ester storage disease at NLA annual meeting

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

Trimeris, Synageva enter definitive merger agreement

Trimeris, Synageva enter definitive merger agreement

Synageva supports Fourth International Rare Disease Day

Synageva supports Fourth International Rare Disease Day

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

FDA grants orphan drug designation for Synageva BioPharma's SBC-102

FDA grants orphan drug designation for Synageva BioPharma's SBC-102

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy